Trilostane for Mules: Uses, Endocrine Questions & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Trilostane is a prescription medication that blocks part of the adrenal gland's steroid production pathway. In dogs, it is FDA-approved for certain forms of Cushing's disease. In mules, its use is off-label, which means your vet may consider it based on medical judgment, but it is not specifically approved for mules or other equids.

For mules, trilostane usually comes up during conversations about endocrine disease, especially when a mule has signs that raise concern for pituitary pars intermedia dysfunction, often called equine Cushing's disease or PPID. Merck notes that pergolide is the equine treatment with the strongest evidence for lowering ACTH in horses with PPID, while trilostane has not been adequately studied in horses even though some clinical improvement has been reported. Because mule-specific research is very limited, your vet has to make decisions carefully and monitor closely.

That matters because mules are not small horses in every medical sense. Drug handling, appetite changes, and subtle behavior shifts can look different in mules than in dogs, and published dosing guidance is sparse. If your mule is being considered for trilostane, your vet will usually focus on the whole picture: exam findings, body condition, coat changes, hoof health, laminitis risk, bloodwork, and endocrine testing rather than the medication alone.

In mules, trilostane is most likely to be discussed when your vet is working through PPID or other adrenal and pituitary questions. Clinical signs that can trigger that workup in equids include delayed shedding or a long haircoat, increased sweating, lethargy, loss of topline muscle, a pendulous abdomen, recurrent infections, hoof abscesses, increased drinking and urination, and laminitis when insulin dysregulation is also present.

Even so, trilostane is not usually the standard first-line choice for equids with suspected PPID. Merck states that pergolide is currently the only agent shown to decrease endogenous ACTH concentrations in horses with PPID. That makes pergolide the medication your vet will often discuss first, with diet changes, hoof care, dental care, and insulin-dysregulation management playing a major role too.

Your vet may still bring up trilostane in selected cases. Examples include a mule with persistent endocrine signs when the diagnosis is still being sorted out, a case where pergolide has not been tolerated well, or a situation where your vet wants a carefully monitored off-label trial. The goal is usually control of clinical signs, not cure, and the plan should always include follow-up testing and reassessment.

There is no well-established, mule-specific standard dose for trilostane. That is one of the biggest reasons this medication should only be used under direct veterinary supervision. In dogs, trilostane is commonly given with food and often requires rechecks 10 to 14 days after starting, then periodic monitoring after that. Those companion-animal principles do not automatically translate to mules, but they highlight how closely this drug needs to be monitored.

If your vet prescribes trilostane for a mule, dosing is usually individualized from the start. Your vet may consider the mule's body weight, age, appetite, kidney and liver values, endocrine test results, laminitis history, and whether the mule is also receiving pergolide or other medications. Because equine evidence is limited, your vet may start conservatively and adjust only after reviewing clinical response and lab work.

Monitoring is a major part of safe use. That can include repeat bloodwork, electrolyte checks, ACTH or other endocrine testing when appropriate, and careful tracking of appetite, manure output, water intake, energy level, and hoof comfort at home. Do not change the dose, skip around between capsule strengths, or stop the medication abruptly unless your vet tells you to. If a dose is missed, call your vet for instructions rather than doubling the next dose.

The most important concern with trilostane is that it can suppress adrenal hormone production too much. In dogs, this can lead to hypoadrenocorticism or an Addisonian-type crisis, which may cause vomiting, diarrhea, weakness, collapse, lethargy, poor appetite, dehydration, and dangerous electrolyte changes. Merck also notes that reversible mineralocorticoid insufficiency can occur, and rare cases of permanent adrenal insufficiency have been reported after trilostane use.

For mules, the exact side-effect pattern is not as well described in published studies, so your vet will usually ask you to watch for broad warning signs. Call your vet promptly if your mule seems dull, stops eating normally, drinks much less, develops diarrhea, appears weak, becomes shaky, lies down more than usual, or seems suddenly foot-sore. Because mules can be stoic, even a mild drop in appetite or attitude can matter.

See your vet immediately if your mule collapses, becomes severely weak, shows signs of dehydration, has profuse diarrhea, or seems acutely painful or distressed. Those signs can point to an emergency, whether the cause is trilostane, laminitis, colic, or another serious problem. Early recognition gives your vet more treatment options.

Trilostane can interact with other medications that affect aldosterone, potassium balance, blood pressure, or kidney perfusion. The clearest documented cautions come from the Vetoryl prescribing information in dogs: ACE inhibitors should be used with caution because both drugs can lower aldosterone effects, and potassium-sparing diuretics such as spironolactone should not be used together because the combination can increase the risk of hyperkalemia.

In a mule, that means your vet should review every prescription, supplement, and feed additive before starting trilostane. This includes pergolide, NSAIDs, diuretics, blood-pressure medications, compounded endocrine drugs, and anything that could affect hydration or kidney function. Even if a product seems routine, the combination may change how safely your mule handles trilostane.

Be sure your vet knows if your mule is pregnant, intended for breeding, has kidney or liver disease, has had previous electrolyte problems, or has recently been treated for another endocrine disorder. Do not open capsules, split them, or handle them casually. Human safety guidance for trilostane includes washing hands after use and avoiding handling by people who are pregnant or trying to conceive.